VALNEVA REPORTS POSITIVE FINAL PHASE 2 ANTIBODY PERSISTENCE AND SAFETY RESULTS IN CHILDREN FOR ITS CHIKUNGUNYA VACCINE IXCHIQ®
94.7% SERORESPONSE RATE IN CHIKV-NAÏVE CHILDREN (FULL DOSE) AT DAY 360
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.